Glycosbio
Houston, US · Delaware corporation · 3 known investors
GlycosBio conducts research and development using engineered lipid technologies to improve the bioavailability and therapeutic performance of natural bioactive molecules, including approaches targeting the intestinal, pulmonary, and skin microbiota. It works with clients on collaborative R&D, clinical validation, and IP licensing of its patented technologies, with research based at the Texas Medical Center in Houston.
Founders & leadership
RC
Richard C. Jr. CilentoNamed on SEC filing
Board
DW
Dan WatkinsBoard director
FF
JW
Joseph WalowskiBoard director
VN
Victoria NiklasBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 3 rounds · 2016–2024
▶$1.1MraisedMar 2024 · 5 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMar 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Victoria NiklasDirector
- John ReplogleDirector
- Richard C. Jr. CilentoExecutive Officer, Director
- Frank FosterDirector
- Joseph WalowskiDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$425KraisedApr 2023 · 3 investors · BiotechnologyRule 506(b)
▶$425KraisedApr 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph WalowskiDirector
- Victoria NiklasDirector
- Richard C. Jr. CilentoExecutive Officer, Director
- Dan WatkinsDirector
- Frank FosterDirector
- Offering amount
- $1M
- Amount sold
- $425K
- Minimum investment
- $25K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$829.8KraisedJan 2017 · 15 investors · Other TechnologyRule 506(b)
▶$829.8KraisedJan 2017 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Frank FosterDirector
- Richard C. CilentoExecutive Officer, Director
- Steve JurvetsonDirector
- Offering amount
- $930K
- Amount sold
- $829.8K
- Minimum investment
- $8K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Glycosbio do?
- GlycosBio conducts research and development using engineered lipid technologies to improve the bioavailability and therapeutic performance of natural bioactive molecules, including approaches targeting the intestinal, pulmonary, and skin microbiota. It works with clients on collaborative R&D, clinical validation, and IP licensing of its patented technologies, with research based at the Texas Medical Center in Houston.
- Who are Glycosbio's investors?
- Glycosbio's investors include Gideon Hixon Fund, Green Park & Golf Ventures, Texas HALO Fund.
- How much funding has Glycosbio raised?
- Glycosbio has disclosed $2.4M raised across 3 rounds.
- Where is Glycosbio headquartered?
- Glycosbio is headquartered in Houston, US.